What is HemoSonics?
Headquartered in Charlottesville, Virginia, HemoSonics operates as a pivotal entity within the Stago group, a global leader in in vitro diagnostics. The company specializes in the development of advanced medical devices designed to provide actionable data in high-stakes critical care environments. Its flagship innovation, the Quantra Hemostasis Analyzer, represents a significant shift in point-of-care bleeding management. By streamlining coagulation analysis, the platform enables clinicians to make rapid, informed decisions that reduce overall medical expenditures while simultaneously improving the standard of patient care. With research and manufacturing operations based in Durham, North Carolina, HemoSonics maintains a robust infrastructure to support its expanding footprint in the thrombosis and hemostasis market.
How much funding has HemoSonics raised?
HemoSonics has raised a total of $25.9M across 6 funding rounds:
Unspecified
$1M
Unspecified
$1.3M
Private Equity
$3.7M
Private Equity
$4M
Private Equity
$15M
Debt
$1M
Unspecified (2008): $1M, investors not publicly disclosed
Unspecified (2013): $1.3M, investors not publicly disclosed
Private Equity (2014): $3.7M, investors not publicly disclosed
Private Equity (2015): $4M, investors not publicly disclosed
Private Equity (2017): $15M, investors not publicly disclosed
Debt (2020): $1M with participation from PPP
Key Investors in HemoSonics
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for HemoSonics?
With the support of its recent capital injection, HemoSonics is well-positioned to scale its diagnostic capabilities and deepen its integration within the broader Stago ecosystem. The strategic focus remains on enhancing the Quantra platform's utility in diverse clinical settings, potentially expanding its reach into new international markets. As the demand for efficient, point-of-care diagnostic tools grows, HemoSonics is expected to prioritize R&D initiatives that further simplify complex hemostasis workflows. This commitment to innovation, backed by sustained financial health, suggests a long-term strategy centered on setting new benchmarks for efficiency and accuracy in critical care medicine.
See full HemoSonics company page
